Ascletis Pharma to Hold 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and Director Re-elections

Bulletin Express06-05

The board of Ascletis Pharma Inc. has issued a notice convening the 2026 Annual General Meeting (AGM) for 09:00 a.m. on Monday, 29 June 2026 at the Four Seasons Hotel Hong Kong, 8 Finance Street, Central.

Key resolutions to be put to shareholders include:

1. Financial Reporting • Receipt and consideration of the audited consolidated financial statements for the year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board Composition and Remuneration • Re-election of Dr. Jinzi Jason Wu as an executive director and Mr. Jiong Gu as an independent non-executive director. • Authorisation for the board to determine directors’ remuneration.

3. Auditor • Re-appointment of KPMG as external auditor and authorisation for the board to set its remuneration.

4. Share Capital Mandates • General mandate allowing the board to allot and issue new shares, including treasury shares, up to 20% of the company’s issued share capital (excluding treasury shares) as at the date of approval. • General mandate permitting repurchase of up to 10% of issued shares (excluding treasury shares) on the Hong Kong Stock Exchange or other recognised exchanges. • Extension of the share-issuance mandate by the number of shares repurchased under the above buy-back authority, capped at an additional 10% of issued share capital.

5. Constitutional Update • Adoption of the third amended and restated memorandum and articles of association.

Administrative details:

• Share transfer books will be closed from Wednesday, 24 June 2026 to Monday, 29 June 2026 (both days inclusive). Transfers for AGM eligibility must be lodged with Computershare Hong Kong Investor Services Limited by 4:30 p.m. on Tuesday, 23 June 2026. • The record date for determining shareholders entitled to attend and vote is Monday, 29 June 2026. • Proxy forms must be deposited with Computershare no later than 09:00 a.m. on Saturday, 27 June 2026.

Board composition at the date of the notice comprises executive directors Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, and independent non-executive directors Dr. Yizhen Wei, Mr. Jiong Gu and Ms. Lin Hua.

Investor enquiries may be directed to ir@ascletis.com.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment